THU-222-The application of novel HBV pgRNA assay to predict HBeAg clearance on long-term nucleos (t)ide analogues

Shah, Pir Ahmad; Idriss, Rajab; Choudhry, Saad; Gersch, Jeffrey; Malladi, Vijayram Reddy; Ishtiaq, Rizwan; Kuhns, Mary C.; Cloherty, Gavin; Lau, Daryl

doi:10.1016/s0618-8278(19)30495-5

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86 In HBeAg-positive patients on NAs with undetectable HBV DNA, the on-treatment decline in HBV RNA levels was a predictor of HBeAg seroconversion. 72,81,87 Another potential role of HBV RNA is to predict the risk of relapse after discontinuation of NAs. In this line, Wang et al found that detection of HBV RNA in patients discontinuing NAs after at least 3 years of therapy was associated with a risk of viral rebound.…”

Section: Serum Hbv Rnamentioning

confidence: 99%

Role of Biomarkers in Guiding Cure of Viral Hepatitis B

et al. 2019

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) virus infection is a global public health threat affecting approximately 257 million individuals worldwide. Hepatitis B surface antigen (HBsAg) loss has been the classic endpoint to define functional cure and decrease the large pool of individuals with CHB. Current treatments with nucleos(t)ide analogues persistently suppress hepatitis B virus (HBV) deoxyribonucleic acid in most CHB patients, but rarely achieve functional cure. New viral biomarkers, such as quantitative HBsAg, hepatitis B core-related antigen, and HBV ribonucleic acid, and combinations of these markers have the potential role of guiding HBV cure by enabling selection of the best candidates for therapy, identifying individuals with a higher likelihood of achieving HBsAg loss, and helping in the design of studies with new drugs. However, some of the assays used to analyze these markers require standardization and improvements in the level of detection. Analysis of host biomarkers to assess the host immune response to HBV is also important, as the natural course of CHB is determined by the interplay between viral replication and the immune response. These biomarkers are, however, in an early phase of development.

show abstract

Section: Serum Hbv Rnamentioning

confidence: 99%

Role of Biomarkers in Guiding Cure of Viral Hepatitis B

et al. 2019

View full text Add to dashboard Cite

show abstract

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B

Campenhout

Bömmel

Pfefferkorn

et al. 2020

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Hepatitis B virus (HBV) RNA in serum is a novel biomarker that reflects cccDNA activity. We investigated whether HBV RNA can predict serological response to peginterferon (PEG‐IFN) treatment. Serum HBV RNA levels were retrospectively measured at weeks 0, 12, 24 and 52 of therapy and after treatment discontinuation (week 78) in 266 HBeAg‐positive chronic HBV patients who had participated in a global randomized controlled trial (HBV99‐01 study). Patients received 52 weeks PEG‐IFN monotherapy (n = 136) or PEG‐IFN and lamivudine (n = 130). The primary end point was HBeAg loss 24 weeks after PEG‐IFN discontinuation. At baseline, the mean serum level of HBV RNA was 6.8 (SD 1.2) log c/mL. HBV RNA levels declined to 4.7 (1.7) log c/mL after one year of PEG‐IFN therapy alone and to 3.3 (1.2)log c/mL after combination therapy. From week 12 onward, HBV RNA level was significantly lower in patients who achieved HBeAg loss at the end of follow‐up as compared to those who did not, regardless of treatment allocation (week 12:4.4 vs 5.1 log c/mL, P = .01; week 24:3.7 vs 4.9 log c/mL, P < .001). The performance of a multivariable model based on HBV RNA level was comparable at week 12 (AUC 0.68) and 24 (AUC 0.72) of therapy. HBV RNA level above 5.5 log c/mL at week 12 showed negative predictive values of 93/67/90/64% for HBV genotypes A/B/C/D for the prediction of HBeAg loss. In conclusion, HBV RNA in serum declines profoundly during PEG‐IFN treatment. Early on‐treatment HBV RNA level may be used to predict nonresponse.

show abstract

THU-222-The application of novel HBV pgRNA assay to predict HBeAg clearance on long-term nucleos (t)ide analogues

Cited by 2 publications

References 0 publications

Role of Biomarkers in Guiding Cure of Viral Hepatitis B

Role of Biomarkers in Guiding Cure of Viral Hepatitis B

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B

Contact Info

Product

Resources

About